What is CBG?
CBG (Cannabigerol) is biochemically the precursor to CBD in the growing hemp plant. It shows i.a. has great potential for treating a wide variety of cancers.
Already 1996 a study was published that positive impact from CBG Melanoma (skin cancer) could prove. It turned out that CBG was able to significantly slow the growth of melanoma cells in the skin of the mice used for the test.
2011 A paper published in the British Journal of Pharmacology examining the medicinal properties of cannabinoids exclusively THC provided many details on that anti-carcinogenic properties from CBG. Several references are cited there according to which the cannabinoid could inhibit tumor formation and cancer cell growth in breast, prostate and other cancers.
A study from the year 2014, in which Italian researchers were involved, showed that CBG interacts positively with processes in the body that are involved in the formation of tumors. Through this interaction, for example Effectively suppresses colon cancer growth become. The study demonstrated this effect using a model experiment with mice suffering from colon cancer. Ultimately, the mice that were given CBG treatment turned out to be one strongly inhibited tumor growth exhibited. This effect comes about because CBG acts as an antagonist of a specific gene that promotes tumor growth (TRPM8), and at the same time also a multitude of others tumor-inhibiting genes activated (including TRPA1, TRPV1 and TRPV2).
CBG- a neuroprotective agent
In the year 2012 A study was published in the 'Journal of Neuroimmune Pharmacology' dealing with CBG and its effects on multiple sclerosis busy. This study, which was carried out by the researchers of 'Vivacell Biotechnology España', was able to confirm that on the one hand, CBG is used as anti-inflammatory substance and on the other hand also as strong neuroprotective agent works. With a test on rodents, the research team was able to prove that CBG helped Making symptoms of MS more tolerableand the influence of key genes that are involved in the development and progression of the disease was also regulated.
2015 researchers from the Department of Biochemistry and Molecular Biology of the 'Universidad Complutense de Madrid 'in Spain work out that CBG strong neuroprotective properties owns. The researchers used 2 different types of for their model Chorea huntington in mice. This disease mostly goes with you progressive breakdown of nerve cells in the brain. The mice treated with CBG showed that CBG was a neuroprotective agent very positive influence took. This was mainly possible through a Improvement of the motor deficits as well as through the Preservation of neurons understand very well. It was also shown that CBG is able to positively influence the influence of genes that are associated with the development and progression of Huntington's disease.
Like the cannabinoids THC and CBD, CBG raises hope that it could provide relief from nerve pain.
Already in the year 2011 'Otsuka Pharmaceutical' and 'GW Pharma' filed a patent claiming that cannabigerol, like other cannabinoids (CBC & CBDV), contributes to the Symptoms of neuropathic pain to be able to alleviate in mice. The research projects of these pharmaceutical companies scientifically prove that CBG helped mice recover from pain caused by surgically induced nerve damage.
Since neuropathic pain tends not to respond to treatment with opiates or similar common joke drugs, CBG enables one completely new perspective for nerve pain as they e.g. Fibromyalgia triggered, affects people. In the study described, it was also found that CBG in the test mice low dosages are most effective released from their nerve pain.
- CBG could be used in cats Glaucoma lower intraocular pressure. (2009)
- A study on rodents found that CBG was beneficial in Treatment of nausea and vomiting can help.
- CBG has in further studies too anti-inflammatory effects in connection with inflammatory bowel disease proven.
Based on the research carried out so far, it appears that cannabigerol has great potential. It is worth mentioning again in this context that it is a non-psychoactive cannabinoid especially noteworthy as many people understandably feel put off by the intoxicating effects of THC.
However, one must not forget that, relatively speaking, the scientific research on CBG is still in its infancy: The scientific studies presented here are not yet sufficient to be able to describe CBG as a finally and fully researched active ingredient.